Pulmonary Rehabilitation for COPD Patients: Can Performance Predict Exacerbation?
Launched by GROUPE HOSPITALIER DU HAVRE · Aug 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how physical performance during pulmonary rehabilitation can help predict worsening symptoms (called exacerbations) in patients with Chronic Obstructive Pulmonary Disease (COPD). The goal of pulmonary rehabilitation is to improve patients' ability to exercise and make breathing easier. Researchers believe that if a patient's ability to exercise decreases during rehabilitation, it might indicate that they are at risk of experiencing a worsening of their condition soon.
To participate in this trial, you must be an adult diagnosed with COPD and have completed at least five sessions of the pulmonary rehabilitation program. However, you won't be eligible if you've had a recent worsening of your COPD symptoms within the last month or if you've experienced any serious health issues that prevent you from continuing rehabilitation. If you join the study, you can expect to undergo regular physical exercises while being monitored to see how well you are doing. This trial aims to help improve the care and management of COPD by finding better ways to predict and prevent exacerbations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients
- • COPD patients
- Exclusion Criteria:
- • Patients who not performed not at least 5 sessions of the pulmonary rehabilitation program
- • Occurence of an adverse event that prevents further rehabilitation
- • Exacerbation in the previous month
About Groupe Hospitalier Du Havre
Groupe Hospitalier du Havre is a prominent healthcare institution in France, dedicated to providing comprehensive medical services and fostering innovative research in clinical care. With a commitment to enhancing patient outcomes, the group actively engages in clinical trials across various therapeutic areas, collaborating with multidisciplinary teams to advance medical knowledge and treatment options. Their state-of-the-art facilities and experienced professionals enable them to conduct rigorous and ethical research, contributing to the global medical community while ensuring the highest standards of patient safety and care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montivilliers, Groupe Hospitalier Du Havre, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials